Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Aloperine inhibits the progression of non-small-cell lung cancer through the PI3K/Akt signaling pathway

Fig. 4

PI3K/AKT/ mTOR signaling pathway, the target of ALO. A549 and H1299 cells were treated with indicated concentrations of ALO for 24 h, and then cells were lysed with RIPA buffer. The cell lysates were analyzed by Western blotting with the indicated antibodies. *P < 0.05, compared to the control group (0 mM, solvent ethanol); #P < 0.05, compared to the ALO group (0.4 mM or 0.3 mM). Data are from one experiment representative of three experiments. Two-tailed Student’s test

Back to article page